KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:开放图源暂不可得 入排置信度 0.98

Immunogenicity and safety of recombinant influenza vaccine versus standard inactivated influenza vaccine in children aged 3 to 8 years: results from a phase III randomised study.

Pedro M Folegatti, Stephanie Pepin, Cynthia Tabar, Katherine Fries, Oxana Talanova, Stephanie See, Kathleen Kaas-Leach, Iris De Bruijn

Vaccine 82 128582

PMID42000149
PMCID-
DOI10.1016/j.vaccine.2026.128582
发表日期2026-04-18
入排依据:未发现恶性肿瘤人群证据。
PubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。
摘要

摘要

Influenza vaccines for those aged <9 years old are limited to the standard-dose inactivated influenza vaccine (IIV) and live-attenuated intranasal influenza vaccine. In this Phase III, modified double-blind, active-controlled trial, participants aged 3-8 years were randomised in a 1:1 ratio to receive the quadrivalent recombinant influenza vaccine (RIV4) or quadrivalent inactivated influenza vaccine (IIV4). The non-inferiority of immune responses was assessed using geometric mean titre ratios (GMTRs) 28 days after the last vaccine administration and seroconversion rates (NCT05513391). A futility analysis was conducted after approximately 25% of the overall sample size was enrolled. Of the 1412 participants planned, 366 participants were enrolled in the United States, Poland, and Spain, resulting in a lower overall study power. The RIV4 induced non-inferior immune responses to those for IIV4 for the A/H1N1, A/H3N2, and B/Yamagata strains but not for the B/Victoria strain. Both vaccines were well tolerated with no safety concerns.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。